血脂康胶囊治疗冠心病血脂异常患者116例临床观察

Clinical Observation on Xuezhikang Capsule for 116 Cases of Coronary Heart Disease with Abnormal Blood Lipid

目的观察血脂康胶囊对痰瘀辨证中不同证候冠心病血脂异常患者的疗效差异。方法对116例经冠状动脉造影确诊为冠心病并经血脂检测诊断为血脂异常的患者进行痰瘀辨证,其中血瘀证30例,痰浊证23例,痰瘀证26例,非痰非瘀证37例。在规范使用冠心病治疗用药的基础上,每次给予血脂康胶囊0.6g,每日2次,连续治疗24周。结果不同证候的患者经血脂康胶囊治疗后,血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)均显著降低(P<0.05),高密度脂蛋白胆固醇(HDL-C)均显著升高(P<0.05);痰浊证组降低TG疗效优于非痰非瘀证组(P<0.01),痰瘀证组升高HDL-C疗效优于非痰非瘀组(P<0.05)。结论血脂康胶囊对冠心病血脂异常不同证候患者均有良好的调脂作用,其降低痰浊证组TG的疗效和升高痰瘀证组HDL-C的疗效要优于非痰非瘀证。

Objective To observe the different effect of Xuezhikang Capsule on the patients of coronary heart disease （CHD） with abnormal blood lipid in different syndromes. Methods Of the 116 patients of CHD with abnormal blood lipid diagnosed by coronary arteriography and blood test, 30 were blood stasis syndrome, 23 phlegm turbid syndrome, 26 phlegm retention syndrome, and 37 nonphlegm non-stasis syndrome. Based on the standard treatment with modern medicine, Xuezhikang Capsule was given 0.6g each time, twice a day, for 24 weeks in succession. Results After the treatment, total cholesterol （TC）, triglyceride （TG） and low density lipoprotein-C （LDL-C） were decreased （P〈0.05）, and high density lipoprotein-C （HDL-C） was increased （P〈0.05） in all patients. In the phlegm turbid group, the effect of TG decrease was superior to that of the non-phlegm non-stasis group （P〈0. 01 ）. In the phlegm retention group, the effect of HDL-C increase was better than that of the non-phlegm non-stasis group （P〈0.05）. Conclusion Xuezhikang Capsule has a good regulation for blood lipid for all the CHD patients with abnormal blood lipid in different syndromes. The effect of TG decrease in the phlegm turbid group and HDL-C increase of in the phlegm retention group was superior to that of the non-phlegm non-stasis group.